Targeting KRAS proteins to enhance immune response against lung tumors
Official title: Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumor
Funded at University of Pittsburgh at Pittsburgh · NIH-11003258 · Data updated 2026-11-12
This study is testing a new way to treat non-small cell lung cancer by using a special method to target and break down certain proteins that are often mutated in this type of cancer, hoping to boost the immune system's ability to fight the tumors and improve options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | December 21, 2023 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $189,756 |
| NIH project number | 5K22CA276357-02 |
| Project ID | NIH-11003258 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS G12C or G12V mutations.
✕Less likely to help
Patients with lung cancer that does not involve KRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on developing a new approach to treat non-small cell lung cancer (NSCLC) by targeting KRAS oncoproteins, which are frequently mutated in lung adenocarcinoma. The study utilizes a novel system called PROTACs to degrade these proteins, potentially enhancing the body's immune response against tumors. By specifically targeting the KRAS G12C and G12V mutations, the research aims to improve treatment outcomes for patients who currently have limited options. Patients may be involved in trials assessing the effectiveness of this innovative treatment strategy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients with KRAS mutations, potentially improving survival rates and quality of life.
How similar studies have gone: Other research has shown promising results with similar approaches targeting KRAS mutations, indicating potential for success in this novel strategy.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Zhang, Hua — University of Pittsburgh at Pittsburgh
- Study coordinator: Zhang, Hua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.